KevinMKalinskyMDMS

Oncology • Atlanta, GA

Hematologic Oncology

Associate Professor of Medicine, Winship Cancer Institute at Emory University

Join to view full profile

Dr. Kalinsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kalinsky's full profile

Already have an account?

Office
1365 Clifton Rd NE
Atlanta, GA 30322
Phone+1 404-778-1900

Fax+1 212-305-0178

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2009
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Tufts Medical CenterResidency, Internal Medicine, 2002 - 2005
Medical University of South CarolinaClass of 2002

Certifications & Licensure

GA State Medical License 2020 - 2025
NY State Medical License 2008 - 2025
MA State Medical License 2006 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 02
Completed
Phase 2
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 1
Adjuvant Valproate for High Grade Sarcomas Start of enrollment: 2009 Oct 01
Terminated
Phase 1
Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 2
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Start of enrollment: 2012 Oct 01
Completed
Phase 2
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Early Phase 1
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 2
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer Start of enrollment: 2016 Mar 01
Completed
Phase 1
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) Start of enrollment: 2016 May 31
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.
Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park
Journal of Clinical Oncology. 2024-12-18
Top advances of the year: Breast cancer.
Clara R Farley, Elizabeth Sakach, Natalie Ridge, Ruth Sacks, Kevin Kalinsky
Cancer. 2024-12-10
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain
Journal of the National Cancer Institute. 2024-12-05

Journal Articles

Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor
Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology

Lectures

Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer. Breast Cancer Immunotherapy: Can We Crack the Code?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

TDXd Better Than Chemo for HER2-Low Breast Cancer?October 3rd, 2024
Copper Depletion Combats Metastatic Recurrence in High-Risk TNBCSeptember 9th, 2024
ASCO 2024: Breast Cancer Trial Updates and TakeawaysJuly 24th, 2024
Join now to see all